Kura Oncology’s Darlifarnib Combo Achieves 44% Response Rate in Difficult-to-Treat RCC—Signals Potential to Overcome Drug Resistance

Robust Tumor Response and High Disease Control Rate Stand Out in Cabozantinib-Pretreated Patients

Kura Oncology announced significant new data from its ongoing FIT-001 clinical trial, revealing that the combination of darlifarnib and cabozantinib led to robust antitumor activity among clear cell renal cell carcinoma (ccRCC) patients who had previously received cabozantinib. In a group that typically sees few meaningful options after disease progression, the therapy achieved an objective response rate (ORR) of 44% and disease control rate (DCR) of 94%—with tumor shrinkage reported in 75% of patients. These results are particularly noteworthy because patients who progress on cabozantinib often show little response to subsequent treatments.

Key Efficacy Data: What Does the FIT-001 Trial Show?

Resensitizing Tumors: Signs Point to Overcoming Cabozantinib Resistance

For patients with advanced ccRCC who have seen their disease progress on cabozantinib, treatment options are sparse and outcomes generally poor. The latest results from Kura’s subset analysis suggest that combining darlifarnib with cabozantinib could help overcome this resistance. Response rates were observed even in heavily pre-treated patients, including those who only achieved stable disease with prior cabozantinib therapy. Notably, some patients achieved durable benefit for over a year, with one-third remaining on treatment at the time of data cutoff.

Manageable Safety Profile Across Multiple Dose Levels

The trial evaluated darlifarnib at 3, 5, and 8 mg doses (alternating 7 days on/off), combined with cabozantinib at either 40 or 60 mg once-daily dosing. Across all regimens, side effects were reported as manageable, aligning with previous studies and supporting continued development of the regime. The ongoing Phase 1b expansion aims to refine dosing and further establish clinical benefit.

Actionable Insight: A Promising Approach for a Refractory Cancer Population

The initial implication is clear: for patients with advanced ccRCC who have exhausted cabozantinib, the darlifarnib-cabozantinib combination offers a promising option. While further studies are warranted, investors and clinicians alike may want to monitor upcoming trial readouts and Kura’s ongoing Phase 1b expansion for signals on long-term outcomes and regulatory progress.

Kura will host a virtual investor event today at 10:30 a.m. ET to discuss these findings, which are also available in more detail on the company’s website.

Key Takeaway

The high response and disease control rates observed in cabozantinib-pretreated ccRCC patients, along with a manageable safety profile, position Kura Oncology’s combination regimen as a noteworthy development for a historically challenging cancer subset. Keep an eye on Kura’s forthcoming clinical milestones to see if these promising early results hold up in larger cohorts.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI